- Yale Dermatology1625 Straits TurnpikeSte Suite 211Middlebury, CT 06762
Christopher Bunick, MD/PhD
Biography
Christopher Bunick, MD, PhD, is a dermatologist who enjoys seeing how happy his patients are when their skin conditions improve. “The confidence they gain to go out into the world and not be shy about the appearance of their skin makes me feel like I am making a difference in people's lives,” says Dr. Bunick, who sees patients in Dermatology’s Middlebury location.
Dr. Bunick treats patients of all ages for all conditions that affect the skin, hair and nails. These run the gamut from pinpointing the cause of a rash to treating eczema, psoriasis, skin lupus, pigment disorders and skin infections. He regularly performs dermatologic surgery for skin cancers and other benign lesions as well.
Having an open and truthful relationship with his patients is both important and deeply rewarding to Dr. Bunick. “First and foremost, I am always honest with my patients, whether the news I am giving them is positive or not. I always reassure them that I will work very hard to help them, even if it takes time to figure out the problem,” he says. “Patients are always welcome to call if they have any questions or concerns.”
When he’s not caring for his patients, Dr. Bunick, who is an associate professor of dermatology for Yale School of Medicine, conducts research on the three-dimensional protein structures that form the skin’s barrier. “My hope is to better understand the molecular mechanisms of the skin barrier, and translate that into better topical therapies for skin issues my patients face,” Dr. Bunick says.
Titles
- Associate Professor of Dermatology
Education & Training
- Medical Education FellowshipYale University (2016)
- Dermatology Research FellowshipYale University School of Medicine (2013)
- ResidencyYale-New Haven Hospital (2012)
- InternshipYale-New Haven Hospital (2009)
- MD/PhDVanderbilt University School of Medicine (2008)
- BSVanderbilt University, molecular biology & mathematics (2000)
Additional Information
- Young Investigator Award: American Academy of Dermatology (2017)
- Career Development Award (Year 3): Dermatology Foundation (2015)
- Career Development Award (Year 2): Dermatology Foundation (2014)
- Bayer Lindau Fellow at the 64th Lindau Nobel Laureate Meeting, Lindau Germany: Bayer Science & Education Foundation (2014)
- Career Development Award: Dermatology Foundation (2013)
- Dermatology Investigator Research Fellowship: Dermatology Foundation (2012)
- Preliminary Year Intern of the Year: Dept. of Internal Medicine, Yale University School of Medicine (2009)
- The Dean’s Award for Research: Vanderbilt University School of Medicine (2008)
- John G. Coniglio Prize in Biochemistry: Dept. of Biochemistry, Vanderbilt University School of Medicine (2008)
- Leon W. Cunningham Graduate Student Biochemistry Award: Dept. of Biochemistry, Vanderbilt University School of Medicine (2004)
- Yale University School of Medicine Faculty Advisory Council (2015 - 2018): Advisor
- Yale Dermatology Residency Program Application Review Committee (2015 - Present): Faculty Member
- Bunick C, Huynh T, Jackson M, Lee L, Kempers S, Mendelsohn A, Eursken B, Ahson A, Raiz J, MC. Teng J. 51523 The Phase 3 Vehicle-Controlled ASCEND Trial of Polyethylene Glycol Based Topical Isotretinoin (TMB-001 0.05% ointment) for Treatment of X-Linked and Autosomal Recessive Congenital Ichthyosis: Pharmacokinetic Results Compared with 80 mg Oral Isotretinoin. Journal Of The American Academy Of Dermatology 2024, 91: ab332. DOI: 10.1016/j.jaad.2024.07.1321.
- van Straalen K, Bunick C, Lobach I, Uhlmann L, Passera A, Alarcon I, Wozniak M, Ravichandran S, Martinez A, da Costa A, Bechara F. 49169 Impact of secukinumab on high-sensitivity C-reactive protein and erythrocyte sedimentation rate: Post hoc analysis of pooled data from the SUNSHINE and SUNRISE Phase 3 randomized trials. Journal Of The American Academy Of Dermatology 2024, 91: ab235. DOI: 10.1016/j.jaad.2024.07.932.
- MacGibeny M, Adjei S, Pyle H, Bunick C, Ghannoum M, Grada A, Harris-Tryon T, Tyring S, Kong H. Alterations in the Skin Microbiome in Dermatologic Diseases and with External Exposures: CME Part 2. Journal Of The American Academy Of Dermatology 2024 PMID: 39173885, DOI: 10.1016/j.jaad.2024.07.1499.
- MacGibeny M, Adjei S, Pyle H, Bunick C, Ghannoum M, Grada A, Harris-Tryon T, Tyring S, Kong H. The Human Skin Microbiome in Health: CME Part 1. Journal Of The American Academy Of Dermatology 2024 PMID: 39168311, DOI: 10.1016/j.jaad.2024.07.1498.
- Bunick C, Grada A, Del Rosso J, Armstrong A, Yue E, Krueger W. 683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study. British Journal Of Dermatology 2024, 191: ljae266.057. DOI: 10.1093/bjd/ljae266.057.
- Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Eyerich K. 734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up). British Journal Of Dermatology 2024, 191: ljae266.107. DOI: 10.1093/bjd/ljae266.107.
- Vleugels R, Grada A, Yue E, Bunick C, Galimberti F, Krueger W. 681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.055. DOI: 10.1093/bjd/ljae266.055.
- Prajapati V, Bunick C, Eyerich K, Gold L, Galimberti F, Calimlim B, Teixeira H, Hu X, Yang Y, Sancho C, Grada A, Irvine A. 696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies. British Journal Of Dermatology 2024, 191: ljae266.070. DOI: 10.1093/bjd/ljae266.070.
- Lebwohl M, Yue E, Krueger W, Berman B, Bunick C, Schlesinger T, Grada A. 697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.071. DOI: 10.1093/bjd/ljae266.071.
- Silverberg J, Calimlim B, Fuxench Z, Altman K, Bensimon A, Liu J, Bunick C. 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study. British Journal Of Dermatology 2024, 191: ljae266.080. DOI: 10.1093/bjd/ljae266.080.
- Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 191: ljae266.021. DOI: 10.1093/bjd/ljae266.021.
- Mostaghimi A, Armstrong A, Grada A, Soliman A, Li C, C Bristow C, Lipiszko D, Silverberg J, Issa N, Bunick C. 699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study. British Journal Of Dermatology 2024, 191: ljae266.073. DOI: 10.1093/bjd/ljae266.073.
- Lomakin I, Devarkar S, Grada A, Bunick C. Mechanistic basis for the translation inhibition of Cutibacterium acnes by Clindamycin. Journal Of Investigative Dermatology 2024 PMID: 39122144, DOI: 10.1016/j.jid.2024.07.013.
- Lomakin I, Devarkar S, Armillei M, Bunick C. 586 Molecular mechanism of protein synthesis inhibition in Cutibacterium acnes by clindamycin. Journal Of Investigative Dermatology 2024, 144: s102. DOI: 10.1016/j.jid.2024.06.602.
- Del Rosso J, Armillei M, Lomakin I, Grada A, Bunick C. Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology. The Journal Of Clinical And Aesthetic Dermatology 2024, 17: 29-40. PMID: 39148960, PMCID: PMC11324192.
- Abdin R, Gharib R, Bunick C, Issa N. Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment. Journal Of Drugs In Dermatology 2024, 23: 694-696. PMID: 39093648, DOI: 10.36849/jdd.8381.
- Issa N, Bunick C. In Response to Reynolds et al.’s “Guidelines of care for the management of acne vulgaris.”. Journal Of The American Academy Of Dermatology 2024 PMID: 38909659, DOI: 10.1016/j.jaad.2024.05.091.
- Kircik L, Stein Gold L, Gold M, Weiss J, Harper J, Del Rosso J, Bunick C, Bhatia N, Tanghetti E, Eichenfield L, Baldwin H, Draelos Z, Callender V, Han G, Gooderham M, Sadick N, Lupo M, Lain E, Werschler W. Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis. Dermatology And Therapy 2024, 14: 1211-1227. PMID: 38724841, PMCID: PMC11116301, DOI: 10.1007/s13555-024-01155-7.
- Del Rosso J, Bunick C, Kircik L, Bhatia N. Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances. Journal Of Drugs In Dermatology 2024, 23: 438-445. PMID: 38834223, DOI: 10.36849/jdd.8318.
- Lomakin I, Ho M, Bunick C. Unveiling the secrets of vimentin filament architecture relevant to human disease. Nature Structural & Molecular Biology 2024, 31: 849-851. PMID: 38684931, DOI: 10.1038/s41594-024-01301-x.
- Altered skin microbiome, inflammation, and JAK/STAT signaling in Southeast Asian ichthyosis patientsHo M, Nguyen H, Van Hoang M, Bui T, Vu B, Dinh T, Vo H, Blaydon D, Eldirany S, Bunick C, Bui C. Altered skin microbiome, inflammation, and JAK/STAT signaling in Southeast Asian ichthyosis patients. Human Genomics 2024, 18: 38. PMID: 38627868, PMCID: PMC11022333, DOI: 10.1186/s40246-024-00603-x.
- Adams R, Bunick C, Lawson A, Gomez B, Shaw S. Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition. Journal Of Investigative Dermatology 2024 PMID: 38631666, DOI: 10.1016/j.jid.2024.03.037.
- Silverberg J, Gooderham M, Paller A, Deleuran M, Bunick C, Gold L, Hijnen D, Calimlim B, Lee W, Teixeira H, Hu X, Zhang S, Yang Y, Grada A, Platt A, Thaçi D. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). American Journal Of Clinical Dermatology 2024, 25: 485-496. PMID: 38528257, PMCID: PMC11070400, DOI: 10.1007/s40257-024-00853-4.
- Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic DiseaseArmillei M, Lomakin I, Del Rosso J, Grada A, Bunick C. Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease. Antibiotics 2024, 13: 270. PMID: 38534705, PMCID: PMC10967556, DOI: 10.3390/antibiotics13030270.
- Huynh F, Damiani G, Bunick C. Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution. Antibiotics 2024, 13: 268. PMID: 38534703, PMCID: PMC10967558, DOI: 10.3390/antibiotics13030268.
- Kucera K, Zenzola N, Hudspeth A, Dubnicka M, Hinz W, Bunick C, Dabestani A, Light D. Benzoyl Peroxide Drug Products Form Benzene. Environmental Health Perspectives 2024, 132: 037702. PMID: 38483533, PMCID: PMC10939128, DOI: 10.1289/ehp13984.
- Bunick C, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Schuttelaar M, Irvine A, Levy G, Platt A, Dilley D, Teixeira H, Altman K, Grada A, Silverberg J. 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure. British Journal Of Dermatology 2024, 190: ii35-ii36. DOI: 10.1093/bjd/ljad498.037.
- Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 190: ii9-ii10. DOI: 10.1093/bjd/ljad498.012.
- Daniele S, Eldirany S, Damiani G, Ho M, Bunick C. Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis. JID Innovations 2024, 4: 100261. PMID: 38445231, PMCID: PMC10914523, DOI: 10.1016/j.xjidi.2024.100261.
- Ghannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s355. DOI: 10.25251/skin.8.supp.355.
- Stein Gold L, Gold M, Kircik L, Harper J, Del Rosso J, Bunick C, Bhatia N, Baldwin H, Draelos Z, Callender V, Lain E. Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s357. DOI: 10.25251/skin.8.supp.357.
- Ghannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s354. DOI: 10.25251/skin.8.supp.354.
- Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Stein Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s309. DOI: 10.25251/skin.8.supp.309.
- Stein Gold L, Gold M, Kircik L, Harper J, Del Rosso J, Bunick C, Bhatia N, Baldwin H, Draelos Z, Callender V, Lain E. Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s339. DOI: 10.25251/skin.8.supp.339.
- Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichnfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Stein Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2023, 7: s251. DOI: 10.25251/skin.7.supp.251.
- Chang J, Nock M, Cohen J, Bunick C. Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002–2016. PLOS ONE 2023, 18: e0290763. PMID: 37733776, PMCID: PMC10513303, DOI: 10.1371/journal.pone.0290763.
- Yousefian F, Hesari R, Jensen T, Obagi S, Rgeai A, Damiani G, Bunick C, Grada A. Antimicrobial Wound Dressings: A Concise Review for Clinicians. Antibiotics 2023, 12: 1434. PMID: 37760730, PMCID: PMC10526066, DOI: 10.3390/antibiotics12091434.
- Lilly E, Bunick C. Congenital Ichthyosis: A Practical Clinical Guide on Current Treatments and Future Perspectives. Clinical Cosmetic And Investigational Dermatology 2023, 16: 2473-2479. PMID: 37719935, PMCID: PMC10503504, DOI: 10.2147/ccid.s388608.
- Bunick C, Daniele S. 43852 JAK inhibitor safety compared to traditional systemic immunosuppressive therapies. Journal Of The American Academy Of Dermatology 2023, 89: ab60. DOI: 10.1016/j.jaad.2023.07.242.
- Ghannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Gold L, Kircik L, Harper J. 43405 Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. Journal Of The American Academy Of Dermatology 2023, 89: ab20. DOI: 10.1016/j.jaad.2023.07.089.
- Silverberg J, Deleuran M, Gold L, Bunick C, Hijnen D, Calimlim B, Teixeira H, Platt A, Grada A, Hu X, Gooderham M. 42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up). Journal Of The American Academy Of Dermatology 2023, 89: ab90. DOI: 10.1016/j.jaad.2023.07.365.
- Borash J, Bunick C, Graber E. Ensuring Dermatologists Practice Enhanced Antibiotic Stewardship With Sarecycline Mnemonic. Journal Of Drugs In Dermatology 2023, 22: 1061. PMID: 37801533, DOI: 10.36849/jdd.7138.
- Damiani G, Pacifico A, Scoditti E, di Gregorio S, Del Fabbro M, Cozzolino C, Buja A, Mercuri S, Bianchi V, Grada A, Garbarino S, Bunick C. Circadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical Study. Dermatology And Therapy 2023, 13: 2229-2246. PMID: 37573289, PMCID: PMC10539244, DOI: 10.1007/s13555-023-00987-z.
- Silverberg J, Bunick C, Lio P, Guttman-Yassky E, Boguniewicz M, Blauvelt A, Bieber T, Thyssen J, Suravaram S, Khan N, Dilley D, Teixeira H, Vigna N, Gamelli A, Grada A, Irvine A. 427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies. British Journal Of Dermatology 2023, 188: ljad162.047. DOI: 10.1093/bjd/ljad162.047.
- Marathe K, Teng J, Guenthner S, Bunick C, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study. Dermatology And Therapy 2023, 13: 1255-1264. PMID: 37170057, PMCID: PMC10264299, DOI: 10.1007/s13555-023-00923-1.
- Lomakin I, Devarkar S, Patel S, Grada A, Bunick C. 1041 Atomic resolution structure of the cutibacterium acnes ribosome reveals the mechanism of protein synthesis inhibition by the antibiotic sarecycline. Journal Of Investigative Dermatology 2023, 143: s178. DOI: 10.1016/j.jid.2023.03.1052.
- Wang J, Bunick C. 1130 Clinically relevant differences in the chemical and structural mechanism of action of dermatological phosphodiesterase-4 inhibitors. Journal Of Investigative Dermatology 2023, 143: s194. DOI: 10.1016/j.jid.2023.03.1142.
- Bui B, Ho M, Bunick C. 831 The skin microbiome and inflammation of Southeast Asian patients with cutaneous ichthyosis. Journal Of Investigative Dermatology 2023, 143: s143. DOI: 10.1016/j.jid.2023.03.841.
- Daniele S, Eldirany S, Bunick C. 1097 The structure of IL-23 inhibitor epitopes correlates with short-term clinical efficacy in plaque psoriasis. Journal Of Investigative Dermatology 2023, 143: s188. DOI: 10.1016/j.jid.2023.03.1109.
- Grada A, Bunick C. Demystifying Hand Eczema. Journal Of Investigative Dermatology 2023, 143: 1338-1339. PMID: 37115112, DOI: 10.1016/j.jid.2023.03.1666.
- Bunick C, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study. Clinical And Experimental Dermatology 2023, 48: 765-769. PMID: 36928932, DOI: 10.1093/ced/llad105.
- Lomakin I, Devarkar S, Patel S, Grada A, Bunick C. Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism. Nucleic Acids Research 2023, 51: 2915-2930. PMID: 36864821, PMCID: PMC10085706, DOI: 10.1093/nar/gkad103.
- Murrell D, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Bunick C. Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis. Clinical And Experimental Dermatology 2023, 48: 623-630. PMID: 36794376, DOI: 10.1093/ced/llad033.
- Grada A, Armstrong A, Bunick C, Salem R, Feldman S. Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016. Journal Of Drugs In Dermatology 2023, 22: 265-270. PMID: 36877883, DOI: 10.36849/jdd.7345.
- Roy S, Sarhan J, Liu X, Murphy M, Bunick C, Choate K, Damsky W, McNiff J. Inguinal patch in mpox (monkeypox) virus infection and eccrine syringometaplasia: report of two cases with in situ hybridization and electron microscopy findings. British Journal Of Dermatology 2022, 188: 574-576. PMID: 36763786, DOI: 10.1093/bjd/ljac146.
- Daniele S, Kim S, Grada A, Moore A, Suozzi K, Bunick C. Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management. American Journal Of Clinical Dermatology 2022, 24: 199-223. PMID: 36539678, DOI: 10.1007/s40257-022-00746-4.
- Grada A, Del Rosso J, Moore A, Gold L, Harper J, Damiani G, Shaw K, Obagi S, Salem R, Tanaka S, Bunick C. Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity. Frontiers In Medicine 2022, 9: 1033980. PMID: 36569144, PMCID: PMC9773825, DOI: 10.3389/fmed.2022.1033980.
- Daniele S, Bunick C. JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies. Journal Of Drugs In Dermatology 2022, 21: 1298-1303. PMID: 36468956, DOI: 10.36849/jdd.7187.
- Belzer A, Weiss E, Etaee F, Bunick CG, Damsky W, Nelson CA. Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature. Antibiotics 2022, 11: 1398. PMID: 36290055, PMCID: PMC9598652, DOI: 10.3390/antibiotics11101398.
- Swallow MA, Fan R, Cohen JM, Bunick CG. Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris. Antibiotics 2022, 11: 1032. PMID: 36009899, PMCID: PMC9405006, DOI: 10.3390/antibiotics11081032.
- Teng JMC, Bunick CG, Guenthner S, Murrell DF, Marathe K, Kempers S, Eads K, Mendelsohn AM, Raiz J, Tavakkol A, Castelo-Soccio L. The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis. Journal Of The American Academy Of Dermatology 2022, 87: 1455-1458. PMID: 35872261, DOI: 10.1016/j.jaad.2022.07.028.
- Grada A, Ghannoum MA, Bunick CG. Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology. Antibiotics 2022, 11: 722. PMID: 35740129, PMCID: PMC9220064, DOI: 10.3390/antibiotics11060722.
- Paller AS, Browning J, Parish LC, Bunick CG, Rome Z, Bhatia N. Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study. Journal Of The American Academy Of Dermatology 2022, 87: 1189-1191. PMID: 35271936, DOI: 10.1016/j.jaad.2022.02.060.
- Ghannoum MA, Long L, Bunick CG, Del Rosso JQ, Gamal A, Tyring SK, McCormick TS, Grada A. Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota. Antibiotics 2022, 11: 324. PMID: 35326788, PMCID: PMC8944611, DOI: 10.3390/antibiotics11030324.
- Ho M, Thompson B, Fisk JN, Nebert DW, Bruford EA, Vasiliou V, Bunick CG. Update of the keratin gene family: evolution, tissue-specific expression patterns, and relevance to clinical disorders. Human Genomics 2022, 16: 1. PMID: 34991727, PMCID: PMC8733776, DOI: 10.1186/s40246-021-00374-9.
- Grada A, Del Rosso JQ, Graber E, Bunick CG, Gold L, Moore AY, Baldwin H, Obagi Z, Damiani G, Carrothers T, McNamee B, Hanze E. Sarecycline treatment for acne vulgaris: Rationale for weight‐based dosing and limited impact of food intake on clinical efficacy. Dermatologic Therapy 2021, 35: e15275. PMID: 34923732, PMCID: PMC9286649, DOI: 10.1111/dth.15275.
- Ogunnigbagbe O, Bunick CG, Kaur K. Keratin 1 as a cell-surface receptor in cancer. Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer 2021, 1877: 188664. PMID: 34890750, PMCID: PMC8818032, DOI: 10.1016/j.bbcan.2021.188664.
- Wu TT, Eldirany SA, Bunick CG, Teng JMC. Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia Congenita. Journal Of Investigative Dermatology 2021, 141: 2876-2884.e4. PMID: 34116063, PMCID: PMC8922998, DOI: 10.1016/j.jid.2021.03.035.
- Bunick C, Del Rosso J, Tyring S, Draper M, Johnson J, Grada A. 199 Activity of sarecycline in murine models of infection and inflammation. Journal Of Investigative Dermatology 2021, 141: s36. DOI: 10.1016/j.jid.2021.02.220.
- Eldirany SA, Ring N, Laskin W, Bunick CG. Dermatomyositis associated with an adrenal adenoma. JAAD Case Reports 2021, 12: 70-73. PMID: 34041336, PMCID: PMC8141419, DOI: 10.1016/j.jdcr.2021.04.012.
- Bunick CG, Keri J, Tanaka SK, Furey N, Damiani G, Johnson JL, Grada A. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. Antibiotics 2021, 10: 439. PMID: 33920812, PMCID: PMC8071131, DOI: 10.3390/antibiotics10040439.
- Grada A, Bunick CG. Spectrum of Antibiotic Activity and Its Relevance to the Microbiome. JAMA Network Open 2021, 4: e215357. PMID: 33914053, DOI: 10.1001/jamanetworkopen.2021.5357.
- Bunick C, Del Rosso J, Tyring S, Draper M, Johnson J, Grada A. Sarecycline Demonstrates Narrow spectrum Antibacterial Activity and Anti inflammatory Effect in Animal Models. SKIN The Journal Of Cutaneous Medicine 2021, 5: s14. DOI: 10.25251/skin.5.supp.14.
- Eldirany SA, Lomakin IB, Ho M, Bunick CG. Recent insight into intermediate filament structure. Current Opinion In Cell Biology 2020, 68: 132-143. PMID: 33190098, PMCID: PMC7925366, DOI: 10.1016/j.ceb.2020.10.001.
- Asabor EN, Bunick CG, Cohen JM, Perkins SH. Patient and physician perspectives on teledermatology at an academic dermatology department amid the COVID-19 pandemic. Journal Of The American Academy Of Dermatology 2020, 84: 158-161. PMID: 32946971, PMCID: PMC7491373, DOI: 10.1016/j.jaad.2020.09.029.
- Hinbest AJ, Eldirany SA, Ho M, Bunick CG. Molecular Modeling of Pathogenic Mutations in the Keratin 1B Domain. International Journal Of Molecular Sciences 2020, 21: 6641. PMID: 32927888, PMCID: PMC7555247, DOI: 10.3390/ijms21186641.
- Hinbest AJ, Kim SR, Eldirany SA, Lomakin IB, Watson J, Ho M, Bunick CG. Structural properties of target binding by profilaggrin A and B domains and other S100 fused-type calcium-binding proteins. Journal Of Dermatological Science 2020, 100: 39-49. PMID: 32893105, PMCID: PMC7752840, DOI: 10.1016/j.jdermsci.2020.08.009.
- Batool Z, Lomakin IB, Polikanov YS, Bunick CG. Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 20530-20537. PMID: 32817463, PMCID: PMC7456112, DOI: 10.1073/pnas.2008671117.
- Batool Z, Lomakin I, Polikanov Y, Bunick C. 576 Crystal structure of sarecycline bound to the 70S bacterial ribosome reveals structural differences from other tetracyclines at atomic resolution. Journal Of Investigative Dermatology 2020, 140: s79. DOI: 10.1016/j.jid.2020.03.586.
- Cohen JM, Bunick CG, Perkins SH. The new normal: An approach to optimizing and combining in-person and telemedicine visits to maximize patient care. Journal Of The American Academy Of Dermatology 2020, 83: e361-e362. PMID: 32593636, PMCID: PMC7316470, DOI: 10.1016/j.jaad.2020.06.075.
- Yumeen S, Mirza FN, Lewis JM, Carlson KR, King B, Cowper S, Bunick CG, McNiff J, Girardi M. CD8+ mycosis fungoides palmaris et plantaris with peripheral blood involvement. JAAD Case Reports 2020, 6: 434-437. PMID: 32382639, PMCID: PMC7200192, DOI: 10.1016/j.jdcr.2020.02.025.
- Perkins S, Cohen JM, Nelson CA, Bunick CG. Teledermatology in the era of COVID-19: Experience of an academic department of dermatology. Journal Of The American Academy Of Dermatology 2020, 83: e43-e44. PMID: 32305442, PMCID: PMC7162755, DOI: 10.1016/j.jaad.2020.04.048.
- Lomakin IB, Hinbest AJ, Ho M, Eldirany SA, Bunick CG. Crystal Structure of Keratin 1/10(C401A) 2B Heterodimer Demonstrates a Proclivity for the C-Terminus of Helix 2B to Form Higher Order Molecular Contacts. The Yale Journal Of Biology And Medicine 2020, 93: 3-17. PMID: 32226330, PMCID: PMC7087056.
- Eldirany SA, Ho M, Bunick CG. Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy. The Yale Journal Of Biology And Medicine 2020, 93: 19-27. PMID: 32226331, PMCID: PMC7087057.
- Eldirany SA, Ho M, Bunick CG. The Interface between Keratin Structurotype and Human Disease. Structure 2020, 28: 271-273. PMID: 32130887, PMCID: PMC7252399, DOI: 10.1016/j.str.2020.02.002.
- Eldirany SA, Myung P, Bunick CG. Ixekizumab-induced alopecia areata. JAAD Case Reports 2019, 6: 51-53. PMID: 31909139, PMCID: PMC6938813, DOI: 10.1016/j.jdcr.2019.10.012.
- Hu JK, Ligtenberg KG, Leventhal J, Bunick CG. Successful management of malodor from fungating tumors using crushed metronidazole tablets. JAAD Case Reports 2019, 6: 26-29. PMID: 31909133, PMCID: PMC6938872, DOI: 10.1016/j.jdcr.2019.10.025.
- Lilly E, Strickler M, Milstone LM, Bunick CG. Alterations in connexin 26 protein structure from lethal keratitis-ichthyosis-deafness syndrome mutations A88V and G45E. Journal Of Dermatological Science 2019, 95: 119-122. PMID: 31331740, PMCID: PMC7263394, DOI: 10.1016/j.jdermsci.2019.07.002.
- Hinbest A, Ho M, Eldirany S, Lomakin I, Bunick C. 339 Keratin 1–keratin 10 helix 1B tetramer crystal structures reveal a knob-pocket mechanism important for proper assembly of intermediate filaments. Journal Of Investigative Dermatology 2019, 139: s58. DOI: 10.1016/j.jid.2019.03.415.
- Eldirany SA, Ho M, Hinbest AJ, Lomakin IB, Bunick CG. Human keratin 1/10‐1B tetramer structures reveal a knob‐pocket mechanism in intermediate filament assembly. The EMBO Journal 2019, 38 PMID: 31036554, PMCID: PMC6545558, DOI: 10.15252/embj.2018100741.
- Lilly E, Bunick CG, Maley AM, Zhang S, Spraker MK, Theos AJ, Vivar KL, Seminario-Vidal L, Bennett AE, Sidbury R, Ogawa Y, Akiyama M, Binder B, Hadj-Rabia S, Morotti RA, Glusac EJ, Choate KA, Richard G, Milstone LM. More than keratitis, ichthyosis, and deafness: Multisystem effects of lethal GJB2 mutations. Journal Of The American Academy Of Dermatology 2018, 80: 617-625. PMID: 30287322, PMCID: PMC6372339, DOI: 10.1016/j.jaad.2018.09.042.
- Eldirany S, Hinbest A, Lomakin I, Bunick C. 689 The x-ray crystal structure of human keratin 1 with S233L mutation demonstrates mechanism of pathogenic tonotubular keratin formation leading to epidermolytic palmoplantar keratoderma. Journal Of Investigative Dermatology 2018, 138: s117. DOI: 10.1016/j.jid.2018.03.698.
- Lomakin I, Hinbest A, Bunick C. 713 The crystal structure of keratin 1/10(Cys401Ala) helix 2B heterodimer determined at 2.0 Å resolution. Journal Of Investigative Dermatology 2018, 138: s121. DOI: 10.1016/j.jid.2018.03.722.
- Bunick C, Lilly E, Milstone L. 452 Alterations to connexin 26 protein structure caused by the lethal keratitis-ichthyosis-deafness syndrome mutations A88V and G45E. Journal Of Investigative Dermatology 2017, 137: s78. DOI: 10.1016/j.jid.2017.02.471.
- Bunick CG, Milstone LM. The X-Ray Crystal Structure of the Keratin 1-Keratin 10 Helix 2B Heterodimer Reveals Molecular Surface Properties and Biochemical Insights into Human Skin Disease. Journal Of Investigative Dermatology 2016, 137: 142-150. PMID: 27595935, PMCID: PMC5514376, DOI: 10.1016/j.jid.2016.08.018.
- Suozzi KC, Stahl M, Ko CJ, Chiang A, Gettinger SN, Siegel MD, Bunick CG. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Reports 2016, 2: 264-268. PMID: 27486590, PMCID: PMC4949498, DOI: 10.1016/j.jdcr.2016.05.002.
- Milstone L, Bunick C. 342 Characterization of the molecular surface properties of keratin 1–keratin 10 intermediate filaments using x-ray crystallography. Journal Of Investigative Dermatology 2016, 136: s60. DOI: 10.1016/j.jid.2016.02.374.
- Bunick C. 376 The x-ray crystal structure of a keratin 1–keratin 10 heterocomplex demonstrates how patient mutations disrupt protein chemistry to cause human keratinopathies. Journal Of Investigative Dermatology 2016, 136: s67. DOI: 10.1016/j.jid.2016.02.409.
- Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic landscape of cutaneous T cell lymphoma. Nature Genetics 2015, 47: 1011-1019. PMID: 26192916, PMCID: PMC4552614, DOI: 10.1038/ng.3356.
- Bunick CG, Presland RB, Lawrence OT, Pearton DJ, Milstone LM, Steitz TA. Crystal Structure of Human Profilaggrin S100 Domain and Identification of Target Proteins Annexin II, Stratifin, and HSP27. Journal Of Investigative Dermatology 2015, 135: 1801-1809. PMID: 25760235, PMCID: PMC4466033, DOI: 10.1038/jid.2015.102.
- Bunick CG. Perspectives on Physiology and Medicine from Nobel Prize Winners: The 64th Lindau Nobel Laureate Meeting. Journal Of Investigative Dermatology 2014, 134: 2853-2855. PMID: 25381760, DOI: 10.1038/jid.2014.358.
- Bunick CG, Miller MR, Fuller BE, Fanning E, Chazin WJ. Biochemical and Structural Domain Analysis of Xeroderma Pigmentosum Complementation Group C Protein †. Biochemistry 2006, 45: 14965-14979. PMID: 17154534, PMCID: PMC2579963, DOI: 10.1021/bi061370o.
- Hanson B, Martin A, Harp J, Parrish D, Bunick C, Kirschbaum K, Pinkerton A, Bunick G. Use of an open‐flow helium cryostat for macromolecular cryocrystallography. Journal Of Applied Crystallography 1999, 32: 814-820. DOI: 10.1107/s0021889899005026.
- Yale Dermatology1625 Straits TurnpikeSte Suite 211Middlebury, CT 06762
Biography
Christopher Bunick, MD, PhD, is a dermatologist who enjoys seeing how happy his patients are when their skin conditions improve. “The confidence they gain to go out into the world and not be shy about the appearance of their skin makes me feel like I am making a difference in people's lives,” says Dr. Bunick, who sees patients in Dermatology’s Middlebury location.
Dr. Bunick treats patients of all ages for all conditions that affect the skin, hair and nails. These run the gamut from pinpointing the cause of a rash to treating eczema, psoriasis, skin lupus, pigment disorders and skin infections. He regularly performs dermatologic surgery for skin cancers and other benign lesions as well.
Having an open and truthful relationship with his patients is both important and deeply rewarding to Dr. Bunick. “First and foremost, I am always honest with my patients, whether the news I am giving them is positive or not. I always reassure them that I will work very hard to help them, even if it takes time to figure out the problem,” he says. “Patients are always welcome to call if they have any questions or concerns.”
When he’s not caring for his patients, Dr. Bunick, who is an associate professor of dermatology for Yale School of Medicine, conducts research on the three-dimensional protein structures that form the skin’s barrier. “My hope is to better understand the molecular mechanisms of the skin barrier, and translate that into better topical therapies for skin issues my patients face,” Dr. Bunick says.
Titles
- Associate Professor of Dermatology
Education & Training
- Medical Education FellowshipYale University (2016)
- Dermatology Research FellowshipYale University School of Medicine (2013)
- ResidencyYale-New Haven Hospital (2012)
- InternshipYale-New Haven Hospital (2009)
- MD/PhDVanderbilt University School of Medicine (2008)
- BSVanderbilt University, molecular biology & mathematics (2000)
Additional Information
- Young Investigator Award: American Academy of Dermatology (2017)
- Career Development Award (Year 3): Dermatology Foundation (2015)
- Career Development Award (Year 2): Dermatology Foundation (2014)
- Bayer Lindau Fellow at the 64th Lindau Nobel Laureate Meeting, Lindau Germany: Bayer Science & Education Foundation (2014)
- Career Development Award: Dermatology Foundation (2013)
- Dermatology Investigator Research Fellowship: Dermatology Foundation (2012)
- Preliminary Year Intern of the Year: Dept. of Internal Medicine, Yale University School of Medicine (2009)
- The Dean’s Award for Research: Vanderbilt University School of Medicine (2008)
- John G. Coniglio Prize in Biochemistry: Dept. of Biochemistry, Vanderbilt University School of Medicine (2008)
- Leon W. Cunningham Graduate Student Biochemistry Award: Dept. of Biochemistry, Vanderbilt University School of Medicine (2004)
- Yale University School of Medicine Faculty Advisory Council (2015 - 2018): Advisor
- Yale Dermatology Residency Program Application Review Committee (2015 - Present): Faculty Member
- Bunick C, Huynh T, Jackson M, Lee L, Kempers S, Mendelsohn A, Eursken B, Ahson A, Raiz J, MC. Teng J. 51523 The Phase 3 Vehicle-Controlled ASCEND Trial of Polyethylene Glycol Based Topical Isotretinoin (TMB-001 0.05% ointment) for Treatment of X-Linked and Autosomal Recessive Congenital Ichthyosis: Pharmacokinetic Results Compared with 80 mg Oral Isotretinoin. Journal Of The American Academy Of Dermatology 2024, 91: ab332. DOI: 10.1016/j.jaad.2024.07.1321.
- van Straalen K, Bunick C, Lobach I, Uhlmann L, Passera A, Alarcon I, Wozniak M, Ravichandran S, Martinez A, da Costa A, Bechara F. 49169 Impact of secukinumab on high-sensitivity C-reactive protein and erythrocyte sedimentation rate: Post hoc analysis of pooled data from the SUNSHINE and SUNRISE Phase 3 randomized trials. Journal Of The American Academy Of Dermatology 2024, 91: ab235. DOI: 10.1016/j.jaad.2024.07.932.
- MacGibeny M, Adjei S, Pyle H, Bunick C, Ghannoum M, Grada A, Harris-Tryon T, Tyring S, Kong H. Alterations in the Skin Microbiome in Dermatologic Diseases and with External Exposures: CME Part 2. Journal Of The American Academy Of Dermatology 2024 PMID: 39173885, DOI: 10.1016/j.jaad.2024.07.1499.
- MacGibeny M, Adjei S, Pyle H, Bunick C, Ghannoum M, Grada A, Harris-Tryon T, Tyring S, Kong H. The Human Skin Microbiome in Health: CME Part 1. Journal Of The American Academy Of Dermatology 2024 PMID: 39168311, DOI: 10.1016/j.jaad.2024.07.1498.
- Bunick C, Grada A, Del Rosso J, Armstrong A, Yue E, Krueger W. 683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study. British Journal Of Dermatology 2024, 191: ljae266.057. DOI: 10.1093/bjd/ljae266.057.
- Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Eyerich K. 734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up). British Journal Of Dermatology 2024, 191: ljae266.107. DOI: 10.1093/bjd/ljae266.107.
- Vleugels R, Grada A, Yue E, Bunick C, Galimberti F, Krueger W. 681 - Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.055. DOI: 10.1093/bjd/ljae266.055.
- Prajapati V, Bunick C, Eyerich K, Gold L, Galimberti F, Calimlim B, Teixeira H, Hu X, Yang Y, Sancho C, Grada A, Irvine A. 696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies. British Journal Of Dermatology 2024, 191: ljae266.070. DOI: 10.1093/bjd/ljae266.070.
- Lebwohl M, Yue E, Krueger W, Berman B, Bunick C, Schlesinger T, Grada A. 697 - Risk of non-melanoma skin cancer in patients with moderate-to-severe atopic dermatitis: a United States population-based study using claims data. British Journal Of Dermatology 2024, 191: ljae266.071. DOI: 10.1093/bjd/ljae266.071.
- Silverberg J, Calimlim B, Fuxench Z, Altman K, Bensimon A, Liu J, Bunick C. 706 - Real-world patient experience of upadacitinib-treated adults with atopic dermatitis: results from the SCALE-UP study. British Journal Of Dermatology 2024, 191: ljae266.080. DOI: 10.1093/bjd/ljae266.080.
- Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 191: ljae266.021. DOI: 10.1093/bjd/ljae266.021.
- Mostaghimi A, Armstrong A, Grada A, Soliman A, Li C, C Bristow C, Lipiszko D, Silverberg J, Issa N, Bunick C. 699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study. British Journal Of Dermatology 2024, 191: ljae266.073. DOI: 10.1093/bjd/ljae266.073.
- Lomakin I, Devarkar S, Grada A, Bunick C. Mechanistic basis for the translation inhibition of Cutibacterium acnes by Clindamycin. Journal Of Investigative Dermatology 2024 PMID: 39122144, DOI: 10.1016/j.jid.2024.07.013.
- Lomakin I, Devarkar S, Armillei M, Bunick C. 586 Molecular mechanism of protein synthesis inhibition in Cutibacterium acnes by clindamycin. Journal Of Investigative Dermatology 2024, 144: s102. DOI: 10.1016/j.jid.2024.06.602.
- Del Rosso J, Armillei M, Lomakin I, Grada A, Bunick C. Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology. The Journal Of Clinical And Aesthetic Dermatology 2024, 17: 29-40. PMID: 39148960, PMCID: PMC11324192.
- Abdin R, Gharib R, Bunick C, Issa N. Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment. Journal Of Drugs In Dermatology 2024, 23: 694-696. PMID: 39093648, DOI: 10.36849/jdd.8381.
- Issa N, Bunick C. In Response to Reynolds et al.’s “Guidelines of care for the management of acne vulgaris.”. Journal Of The American Academy Of Dermatology 2024 PMID: 38909659, DOI: 10.1016/j.jaad.2024.05.091.
- Kircik L, Stein Gold L, Gold M, Weiss J, Harper J, Del Rosso J, Bunick C, Bhatia N, Tanghetti E, Eichenfield L, Baldwin H, Draelos Z, Callender V, Han G, Gooderham M, Sadick N, Lupo M, Lain E, Werschler W. Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis. Dermatology And Therapy 2024, 14: 1211-1227. PMID: 38724841, PMCID: PMC11116301, DOI: 10.1007/s13555-024-01155-7.
- Del Rosso J, Bunick C, Kircik L, Bhatia N. Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances. Journal Of Drugs In Dermatology 2024, 23: 438-445. PMID: 38834223, DOI: 10.36849/jdd.8318.
- Lomakin I, Ho M, Bunick C. Unveiling the secrets of vimentin filament architecture relevant to human disease. Nature Structural & Molecular Biology 2024, 31: 849-851. PMID: 38684931, DOI: 10.1038/s41594-024-01301-x.
- Altered skin microbiome, inflammation, and JAK/STAT signaling in Southeast Asian ichthyosis patientsHo M, Nguyen H, Van Hoang M, Bui T, Vu B, Dinh T, Vo H, Blaydon D, Eldirany S, Bunick C, Bui C. Altered skin microbiome, inflammation, and JAK/STAT signaling in Southeast Asian ichthyosis patients. Human Genomics 2024, 18: 38. PMID: 38627868, PMCID: PMC11022333, DOI: 10.1186/s40246-024-00603-x.
- Adams R, Bunick C, Lawson A, Gomez B, Shaw S. Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition. Journal Of Investigative Dermatology 2024 PMID: 38631666, DOI: 10.1016/j.jid.2024.03.037.
- Silverberg J, Gooderham M, Paller A, Deleuran M, Bunick C, Gold L, Hijnen D, Calimlim B, Lee W, Teixeira H, Hu X, Zhang S, Yang Y, Grada A, Platt A, Thaçi D. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). American Journal Of Clinical Dermatology 2024, 25: 485-496. PMID: 38528257, PMCID: PMC11070400, DOI: 10.1007/s40257-024-00853-4.
- Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic DiseaseArmillei M, Lomakin I, Del Rosso J, Grada A, Bunick C. Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease. Antibiotics 2024, 13: 270. PMID: 38534705, PMCID: PMC10967556, DOI: 10.3390/antibiotics13030270.
- Huynh F, Damiani G, Bunick C. Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution. Antibiotics 2024, 13: 268. PMID: 38534703, PMCID: PMC10967558, DOI: 10.3390/antibiotics13030268.
- Kucera K, Zenzola N, Hudspeth A, Dubnicka M, Hinz W, Bunick C, Dabestani A, Light D. Benzoyl Peroxide Drug Products Form Benzene. Environmental Health Perspectives 2024, 132: 037702. PMID: 38483533, PMCID: PMC10939128, DOI: 10.1289/ehp13984.
- Bunick C, Chovatiya R, Guttman E, Shahriari M, Boguniewicz M, Gao X, Greiwe J, Blauvelt A, Schuttelaar M, Irvine A, Levy G, Platt A, Dilley D, Teixeira H, Altman K, Grada A, Silverberg J. 533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure. British Journal Of Dermatology 2024, 190: ii35-ii36. DOI: 10.1093/bjd/ljad498.037.
- Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. 504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis. British Journal Of Dermatology 2024, 190: ii9-ii10. DOI: 10.1093/bjd/ljad498.012.
- Daniele S, Eldirany S, Damiani G, Ho M, Bunick C. Structural Basis for p19 Targeting by Anti–IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis. JID Innovations 2024, 4: 100261. PMID: 38445231, PMCID: PMC10914523, DOI: 10.1016/j.xjidi.2024.100261.
- Ghannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s355. DOI: 10.25251/skin.8.supp.355.
- Stein Gold L, Gold M, Kircik L, Harper J, Del Rosso J, Bunick C, Bhatia N, Baldwin H, Draelos Z, Callender V, Lain E. Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s357. DOI: 10.25251/skin.8.supp.357.
- Ghannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s354. DOI: 10.25251/skin.8.supp.354.
- Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichenfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Stein Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s309. DOI: 10.25251/skin.8.supp.309.
- Stein Gold L, Gold M, Kircik L, Harper J, Del Rosso J, Bunick C, Bhatia N, Baldwin H, Draelos Z, Callender V, Lain E. Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s339. DOI: 10.25251/skin.8.supp.339.
- Bunick C, Bhatia N, Del Rosso J, Draelos Z, Eichnfield L, Kircik L, Lebwohl M, Gooderham M, Green L, Hebert A, Vender R, Zirwas M, Simpson E, Stein Gold L, Seal M, Snyder S, Osborne D, Burnett P, Higham R, Chu D, Berk D. Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2023, 7: s251. DOI: 10.25251/skin.7.supp.251.
- Chang J, Nock M, Cohen J, Bunick C. Acne accounts for an almost 2.5-fold higher proportion of dermatology visits among adult females compared to adult males in the United States: A study of the national ambulatory medical care survey from 2002–2016. PLOS ONE 2023, 18: e0290763. PMID: 37733776, PMCID: PMC10513303, DOI: 10.1371/journal.pone.0290763.
- Yousefian F, Hesari R, Jensen T, Obagi S, Rgeai A, Damiani G, Bunick C, Grada A. Antimicrobial Wound Dressings: A Concise Review for Clinicians. Antibiotics 2023, 12: 1434. PMID: 37760730, PMCID: PMC10526066, DOI: 10.3390/antibiotics12091434.
- Lilly E, Bunick C. Congenital Ichthyosis: A Practical Clinical Guide on Current Treatments and Future Perspectives. Clinical Cosmetic And Investigational Dermatology 2023, 16: 2473-2479. PMID: 37719935, PMCID: PMC10503504, DOI: 10.2147/ccid.s388608.
- Bunick C, Daniele S. 43852 JAK inhibitor safety compared to traditional systemic immunosuppressive therapies. Journal Of The American Academy Of Dermatology 2023, 89: ab60. DOI: 10.1016/j.jaad.2023.07.242.
- Ghannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Gold L, Kircik L, Harper J. 43405 Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. Journal Of The American Academy Of Dermatology 2023, 89: ab20. DOI: 10.1016/j.jaad.2023.07.089.
- Silverberg J, Deleuran M, Gold L, Bunick C, Hijnen D, Calimlim B, Teixeira H, Platt A, Grada A, Hu X, Gooderham M. 42262 Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up). Journal Of The American Academy Of Dermatology 2023, 89: ab90. DOI: 10.1016/j.jaad.2023.07.365.
- Borash J, Bunick C, Graber E. Ensuring Dermatologists Practice Enhanced Antibiotic Stewardship With Sarecycline Mnemonic. Journal Of Drugs In Dermatology 2023, 22: 1061. PMID: 37801533, DOI: 10.36849/jdd.7138.
- Damiani G, Pacifico A, Scoditti E, di Gregorio S, Del Fabbro M, Cozzolino C, Buja A, Mercuri S, Bianchi V, Grada A, Garbarino S, Bunick C. Circadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical Study. Dermatology And Therapy 2023, 13: 2229-2246. PMID: 37573289, PMCID: PMC10539244, DOI: 10.1007/s13555-023-00987-z.
- Silverberg J, Bunick C, Lio P, Guttman-Yassky E, Boguniewicz M, Blauvelt A, Bieber T, Thyssen J, Suravaram S, Khan N, Dilley D, Teixeira H, Vigna N, Gamelli A, Grada A, Irvine A. 427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies. British Journal Of Dermatology 2023, 188: ljad162.047. DOI: 10.1093/bjd/ljad162.047.
- Marathe K, Teng J, Guenthner S, Bunick C, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study. Dermatology And Therapy 2023, 13: 1255-1264. PMID: 37170057, PMCID: PMC10264299, DOI: 10.1007/s13555-023-00923-1.
- Lomakin I, Devarkar S, Patel S, Grada A, Bunick C. 1041 Atomic resolution structure of the cutibacterium acnes ribosome reveals the mechanism of protein synthesis inhibition by the antibiotic sarecycline. Journal Of Investigative Dermatology 2023, 143: s178. DOI: 10.1016/j.jid.2023.03.1052.
- Wang J, Bunick C. 1130 Clinically relevant differences in the chemical and structural mechanism of action of dermatological phosphodiesterase-4 inhibitors. Journal Of Investigative Dermatology 2023, 143: s194. DOI: 10.1016/j.jid.2023.03.1142.
- Bui B, Ho M, Bunick C. 831 The skin microbiome and inflammation of Southeast Asian patients with cutaneous ichthyosis. Journal Of Investigative Dermatology 2023, 143: s143. DOI: 10.1016/j.jid.2023.03.841.
- Daniele S, Eldirany S, Bunick C. 1097 The structure of IL-23 inhibitor epitopes correlates with short-term clinical efficacy in plaque psoriasis. Journal Of Investigative Dermatology 2023, 143: s188. DOI: 10.1016/j.jid.2023.03.1109.
- Grada A, Bunick C. Demystifying Hand Eczema. Journal Of Investigative Dermatology 2023, 143: 1338-1339. PMID: 37115112, DOI: 10.1016/j.jid.2023.03.1666.
- Bunick C, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study. Clinical And Experimental Dermatology 2023, 48: 765-769. PMID: 36928932, DOI: 10.1093/ced/llad105.
- Lomakin I, Devarkar S, Patel S, Grada A, Bunick C. Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism. Nucleic Acids Research 2023, 51: 2915-2930. PMID: 36864821, PMCID: PMC10085706, DOI: 10.1093/nar/gkad103.
- Murrell D, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Bunick C. Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis. Clinical And Experimental Dermatology 2023, 48: 623-630. PMID: 36794376, DOI: 10.1093/ced/llad033.
- Grada A, Armstrong A, Bunick C, Salem R, Feldman S. Trends in Oral Antibiotic Use for Acne Treatment: A Retrospective, Population-Based Study in the United States, 2014 to 2016. Journal Of Drugs In Dermatology 2023, 22: 265-270. PMID: 36877883, DOI: 10.36849/jdd.7345.
- Roy S, Sarhan J, Liu X, Murphy M, Bunick C, Choate K, Damsky W, McNiff J. Inguinal patch in mpox (monkeypox) virus infection and eccrine syringometaplasia: report of two cases with in situ hybridization and electron microscopy findings. British Journal Of Dermatology 2022, 188: 574-576. PMID: 36763786, DOI: 10.1093/bjd/ljac146.
- Daniele S, Kim S, Grada A, Moore A, Suozzi K, Bunick C. Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management. American Journal Of Clinical Dermatology 2022, 24: 199-223. PMID: 36539678, DOI: 10.1007/s40257-022-00746-4.
- Grada A, Del Rosso J, Moore A, Gold L, Harper J, Damiani G, Shaw K, Obagi S, Salem R, Tanaka S, Bunick C. Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity. Frontiers In Medicine 2022, 9: 1033980. PMID: 36569144, PMCID: PMC9773825, DOI: 10.3389/fmed.2022.1033980.
- Daniele S, Bunick C. JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies. Journal Of Drugs In Dermatology 2022, 21: 1298-1303. PMID: 36468956, DOI: 10.36849/jdd.7187.
- Belzer A, Weiss E, Etaee F, Bunick CG, Damsky W, Nelson CA. Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature. Antibiotics 2022, 11: 1398. PMID: 36290055, PMCID: PMC9598652, DOI: 10.3390/antibiotics11101398.
- Swallow MA, Fan R, Cohen JM, Bunick CG. Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris. Antibiotics 2022, 11: 1032. PMID: 36009899, PMCID: PMC9405006, DOI: 10.3390/antibiotics11081032.
- Teng JMC, Bunick CG, Guenthner S, Murrell DF, Marathe K, Kempers S, Eads K, Mendelsohn AM, Raiz J, Tavakkol A, Castelo-Soccio L. The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis. Journal Of The American Academy Of Dermatology 2022, 87: 1455-1458. PMID: 35872261, DOI: 10.1016/j.jaad.2022.07.028.
- Grada A, Ghannoum MA, Bunick CG. Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology. Antibiotics 2022, 11: 722. PMID: 35740129, PMCID: PMC9220064, DOI: 10.3390/antibiotics11060722.
- Paller AS, Browning J, Parish LC, Bunick CG, Rome Z, Bhatia N. Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study. Journal Of The American Academy Of Dermatology 2022, 87: 1189-1191. PMID: 35271936, DOI: 10.1016/j.jaad.2022.02.060.
- Ghannoum MA, Long L, Bunick CG, Del Rosso JQ, Gamal A, Tyring SK, McCormick TS, Grada A. Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota. Antibiotics 2022, 11: 324. PMID: 35326788, PMCID: PMC8944611, DOI: 10.3390/antibiotics11030324.
- Ho M, Thompson B, Fisk JN, Nebert DW, Bruford EA, Vasiliou V, Bunick CG. Update of the keratin gene family: evolution, tissue-specific expression patterns, and relevance to clinical disorders. Human Genomics 2022, 16: 1. PMID: 34991727, PMCID: PMC8733776, DOI: 10.1186/s40246-021-00374-9.
- Grada A, Del Rosso JQ, Graber E, Bunick CG, Gold L, Moore AY, Baldwin H, Obagi Z, Damiani G, Carrothers T, McNamee B, Hanze E. Sarecycline treatment for acne vulgaris: Rationale for weight‐based dosing and limited impact of food intake on clinical efficacy. Dermatologic Therapy 2021, 35: e15275. PMID: 34923732, PMCID: PMC9286649, DOI: 10.1111/dth.15275.
- Ogunnigbagbe O, Bunick CG, Kaur K. Keratin 1 as a cell-surface receptor in cancer. Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer 2021, 1877: 188664. PMID: 34890750, PMCID: PMC8818032, DOI: 10.1016/j.bbcan.2021.188664.
- Wu TT, Eldirany SA, Bunick CG, Teng JMC. Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia Congenita. Journal Of Investigative Dermatology 2021, 141: 2876-2884.e4. PMID: 34116063, PMCID: PMC8922998, DOI: 10.1016/j.jid.2021.03.035.
- Bunick C, Del Rosso J, Tyring S, Draper M, Johnson J, Grada A. 199 Activity of sarecycline in murine models of infection and inflammation. Journal Of Investigative Dermatology 2021, 141: s36. DOI: 10.1016/j.jid.2021.02.220.
- Eldirany SA, Ring N, Laskin W, Bunick CG. Dermatomyositis associated with an adrenal adenoma. JAAD Case Reports 2021, 12: 70-73. PMID: 34041336, PMCID: PMC8141419, DOI: 10.1016/j.jdcr.2021.04.012.
- Bunick CG, Keri J, Tanaka SK, Furey N, Damiani G, Johnson JL, Grada A. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. Antibiotics 2021, 10: 439. PMID: 33920812, PMCID: PMC8071131, DOI: 10.3390/antibiotics10040439.
- Grada A, Bunick CG. Spectrum of Antibiotic Activity and Its Relevance to the Microbiome. JAMA Network Open 2021, 4: e215357. PMID: 33914053, DOI: 10.1001/jamanetworkopen.2021.5357.
- Bunick C, Del Rosso J, Tyring S, Draper M, Johnson J, Grada A. Sarecycline Demonstrates Narrow spectrum Antibacterial Activity and Anti inflammatory Effect in Animal Models. SKIN The Journal Of Cutaneous Medicine 2021, 5: s14. DOI: 10.25251/skin.5.supp.14.
- Eldirany SA, Lomakin IB, Ho M, Bunick CG. Recent insight into intermediate filament structure. Current Opinion In Cell Biology 2020, 68: 132-143. PMID: 33190098, PMCID: PMC7925366, DOI: 10.1016/j.ceb.2020.10.001.
- Asabor EN, Bunick CG, Cohen JM, Perkins SH. Patient and physician perspectives on teledermatology at an academic dermatology department amid the COVID-19 pandemic. Journal Of The American Academy Of Dermatology 2020, 84: 158-161. PMID: 32946971, PMCID: PMC7491373, DOI: 10.1016/j.jaad.2020.09.029.
- Hinbest AJ, Eldirany SA, Ho M, Bunick CG. Molecular Modeling of Pathogenic Mutations in the Keratin 1B Domain. International Journal Of Molecular Sciences 2020, 21: 6641. PMID: 32927888, PMCID: PMC7555247, DOI: 10.3390/ijms21186641.
- Hinbest AJ, Kim SR, Eldirany SA, Lomakin IB, Watson J, Ho M, Bunick CG. Structural properties of target binding by profilaggrin A and B domains and other S100 fused-type calcium-binding proteins. Journal Of Dermatological Science 2020, 100: 39-49. PMID: 32893105, PMCID: PMC7752840, DOI: 10.1016/j.jdermsci.2020.08.009.
- Batool Z, Lomakin IB, Polikanov YS, Bunick CG. Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 20530-20537. PMID: 32817463, PMCID: PMC7456112, DOI: 10.1073/pnas.2008671117.
- Batool Z, Lomakin I, Polikanov Y, Bunick C. 576 Crystal structure of sarecycline bound to the 70S bacterial ribosome reveals structural differences from other tetracyclines at atomic resolution. Journal Of Investigative Dermatology 2020, 140: s79. DOI: 10.1016/j.jid.2020.03.586.
- Cohen JM, Bunick CG, Perkins SH. The new normal: An approach to optimizing and combining in-person and telemedicine visits to maximize patient care. Journal Of The American Academy Of Dermatology 2020, 83: e361-e362. PMID: 32593636, PMCID: PMC7316470, DOI: 10.1016/j.jaad.2020.06.075.
- Yumeen S, Mirza FN, Lewis JM, Carlson KR, King B, Cowper S, Bunick CG, McNiff J, Girardi M. CD8+ mycosis fungoides palmaris et plantaris with peripheral blood involvement. JAAD Case Reports 2020, 6: 434-437. PMID: 32382639, PMCID: PMC7200192, DOI: 10.1016/j.jdcr.2020.02.025.
- Perkins S, Cohen JM, Nelson CA, Bunick CG. Teledermatology in the era of COVID-19: Experience of an academic department of dermatology. Journal Of The American Academy Of Dermatology 2020, 83: e43-e44. PMID: 32305442, PMCID: PMC7162755, DOI: 10.1016/j.jaad.2020.04.048.
- Lomakin IB, Hinbest AJ, Ho M, Eldirany SA, Bunick CG. Crystal Structure of Keratin 1/10(C401A) 2B Heterodimer Demonstrates a Proclivity for the C-Terminus of Helix 2B to Form Higher Order Molecular Contacts. The Yale Journal Of Biology And Medicine 2020, 93: 3-17. PMID: 32226330, PMCID: PMC7087056.
- Eldirany SA, Ho M, Bunick CG. Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy. The Yale Journal Of Biology And Medicine 2020, 93: 19-27. PMID: 32226331, PMCID: PMC7087057.
- Eldirany SA, Ho M, Bunick CG. The Interface between Keratin Structurotype and Human Disease. Structure 2020, 28: 271-273. PMID: 32130887, PMCID: PMC7252399, DOI: 10.1016/j.str.2020.02.002.
- Eldirany SA, Myung P, Bunick CG. Ixekizumab-induced alopecia areata. JAAD Case Reports 2019, 6: 51-53. PMID: 31909139, PMCID: PMC6938813, DOI: 10.1016/j.jdcr.2019.10.012.
- Hu JK, Ligtenberg KG, Leventhal J, Bunick CG. Successful management of malodor from fungating tumors using crushed metronidazole tablets. JAAD Case Reports 2019, 6: 26-29. PMID: 31909133, PMCID: PMC6938872, DOI: 10.1016/j.jdcr.2019.10.025.
- Lilly E, Strickler M, Milstone LM, Bunick CG. Alterations in connexin 26 protein structure from lethal keratitis-ichthyosis-deafness syndrome mutations A88V and G45E. Journal Of Dermatological Science 2019, 95: 119-122. PMID: 31331740, PMCID: PMC7263394, DOI: 10.1016/j.jdermsci.2019.07.002.
- Hinbest A, Ho M, Eldirany S, Lomakin I, Bunick C. 339 Keratin 1–keratin 10 helix 1B tetramer crystal structures reveal a knob-pocket mechanism important for proper assembly of intermediate filaments. Journal Of Investigative Dermatology 2019, 139: s58. DOI: 10.1016/j.jid.2019.03.415.
- Eldirany SA, Ho M, Hinbest AJ, Lomakin IB, Bunick CG. Human keratin 1/10‐1B tetramer structures reveal a knob‐pocket mechanism in intermediate filament assembly. The EMBO Journal 2019, 38 PMID: 31036554, PMCID: PMC6545558, DOI: 10.15252/embj.2018100741.
- Lilly E, Bunick CG, Maley AM, Zhang S, Spraker MK, Theos AJ, Vivar KL, Seminario-Vidal L, Bennett AE, Sidbury R, Ogawa Y, Akiyama M, Binder B, Hadj-Rabia S, Morotti RA, Glusac EJ, Choate KA, Richard G, Milstone LM. More than keratitis, ichthyosis, and deafness: Multisystem effects of lethal GJB2 mutations. Journal Of The American Academy Of Dermatology 2018, 80: 617-625. PMID: 30287322, PMCID: PMC6372339, DOI: 10.1016/j.jaad.2018.09.042.
- Eldirany S, Hinbest A, Lomakin I, Bunick C. 689 The x-ray crystal structure of human keratin 1 with S233L mutation demonstrates mechanism of pathogenic tonotubular keratin formation leading to epidermolytic palmoplantar keratoderma. Journal Of Investigative Dermatology 2018, 138: s117. DOI: 10.1016/j.jid.2018.03.698.
- Lomakin I, Hinbest A, Bunick C. 713 The crystal structure of keratin 1/10(Cys401Ala) helix 2B heterodimer determined at 2.0 Å resolution. Journal Of Investigative Dermatology 2018, 138: s121. DOI: 10.1016/j.jid.2018.03.722.
- Bunick C, Lilly E, Milstone L. 452 Alterations to connexin 26 protein structure caused by the lethal keratitis-ichthyosis-deafness syndrome mutations A88V and G45E. Journal Of Investigative Dermatology 2017, 137: s78. DOI: 10.1016/j.jid.2017.02.471.
- Bunick CG, Milstone LM. The X-Ray Crystal Structure of the Keratin 1-Keratin 10 Helix 2B Heterodimer Reveals Molecular Surface Properties and Biochemical Insights into Human Skin Disease. Journal Of Investigative Dermatology 2016, 137: 142-150. PMID: 27595935, PMCID: PMC5514376, DOI: 10.1016/j.jid.2016.08.018.
- Suozzi KC, Stahl M, Ko CJ, Chiang A, Gettinger SN, Siegel MD, Bunick CG. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Reports 2016, 2: 264-268. PMID: 27486590, PMCID: PMC4949498, DOI: 10.1016/j.jdcr.2016.05.002.
- Milstone L, Bunick C. 342 Characterization of the molecular surface properties of keratin 1–keratin 10 intermediate filaments using x-ray crystallography. Journal Of Investigative Dermatology 2016, 136: s60. DOI: 10.1016/j.jid.2016.02.374.
- Bunick C. 376 The x-ray crystal structure of a keratin 1–keratin 10 heterocomplex demonstrates how patient mutations disrupt protein chemistry to cause human keratinopathies. Journal Of Investigative Dermatology 2016, 136: s67. DOI: 10.1016/j.jid.2016.02.409.
- Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP. Genomic landscape of cutaneous T cell lymphoma. Nature Genetics 2015, 47: 1011-1019. PMID: 26192916, PMCID: PMC4552614, DOI: 10.1038/ng.3356.
- Bunick CG, Presland RB, Lawrence OT, Pearton DJ, Milstone LM, Steitz TA. Crystal Structure of Human Profilaggrin S100 Domain and Identification of Target Proteins Annexin II, Stratifin, and HSP27. Journal Of Investigative Dermatology 2015, 135: 1801-1809. PMID: 25760235, PMCID: PMC4466033, DOI: 10.1038/jid.2015.102.
- Bunick CG. Perspectives on Physiology and Medicine from Nobel Prize Winners: The 64th Lindau Nobel Laureate Meeting. Journal Of Investigative Dermatology 2014, 134: 2853-2855. PMID: 25381760, DOI: 10.1038/jid.2014.358.
- Bunick CG, Miller MR, Fuller BE, Fanning E, Chazin WJ. Biochemical and Structural Domain Analysis of Xeroderma Pigmentosum Complementation Group C Protein †. Biochemistry 2006, 45: 14965-14979. PMID: 17154534, PMCID: PMC2579963, DOI: 10.1021/bi061370o.
- Hanson B, Martin A, Harp J, Parrish D, Bunick C, Kirschbaum K, Pinkerton A, Bunick G. Use of an open‐flow helium cryostat for macromolecular cryocrystallography. Journal Of Applied Crystallography 1999, 32: 814-820. DOI: 10.1107/s0021889899005026.
- Yale Dermatology1625 Straits TurnpikeSte Suite 211Middlebury, CT 06762
- Yale Dermatology1625 Straits TurnpikeSte Suite 211Middlebury, CT 06762